A new study finds that drug company representatives visiting doctors leads to more prescriptions for cancer patients, but it does not result in longer survival. The researchers used Medicare claims data and the Open Payments database to track drug company payments to doctors and found that doctors prescribed about 5% more oncology drugs following a visit from a pharmaceutical representative. However, the study also found that the practice did not make cancer patients live longer.